Phase i studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma

Masafumi Ikeda; Takuji Okusaka; Izumi Ohno; Shuichi Mitsunaga; Shunsuke Kondo; Hideki Ueno; Chigusa Morizane; Kazuto Gemmoto; Hideaki Suna; Yasunori Ushida; Junji Furuse

doi:10.2217/imt-2020-0278

Phase i studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma

Masafumi Ikeda, Takuji Okusaka, Izumi Ohno, Shuichi Mitsunaga, Shunsuke Kondo, Hideki Ueno, Chigusa Morizane, Kazuto Gemmoto, Hideaki Suna, Yasunori Ushida, Junji Furuse

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Aim: Two peptide cocktail vaccines using glypican-3, WD-repeat-containing protein up-regulated in hepatocellular carcinoma (HCC) and nei endonuclease VIII-like three epitopes were evaluated in advanced HCC in two Phase I studies. Patients & methods: Study 1 evaluated dose-limiting toxicities (DLTs) of peptides 1-3 (HLA-A24-restricted) and study 2 evaluated DLTs of peptides 1-6 (HLA-A24 or A02-restricted). Results: Overall, 18 and 14 patients were enrolled in studies 1 and 2, respectively. No DLTs were observed up to 7.1 mg of the vaccine cocktail. No complete response/partial response was observed. Stable disease was reported in nine and five patients with a disease control rate of 52.9% and 35.7% in studies 1 and 2, respectively. Conclusion: Both vaccines showed good tolerability and potential usefulness against HCC. Clinical trial registration: JapicCTI-121933; JapicCTI-142477</ext-link.

Original language	English
Pages (from-to)	371-385
Number of pages	15
Journal	Immunotherapy
Volume	13
Issue number	5
DOIs	https://doi.org/10.2217/imt-2020-0278
State	Published - Apr 2021
Externally published	Yes

Keywords

GPC3
HCC
hepatocellular carcinoma
NEIL3
Phase I studies
WDRPUH

Access to Document

10.2217/imt-2020-0278

Cite this

@article{d14a81ce6f954075b7f846184e905f2b,

title = "Phase i studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma",

abstract = "Aim: Two peptide cocktail vaccines using glypican-3, WD-repeat-containing protein up-regulated in hepatocellular carcinoma (HCC) and nei endonuclease VIII-like three epitopes were evaluated in advanced HCC in two Phase I studies. Patients & methods: Study 1 evaluated dose-limiting toxicities (DLTs) of peptides 1-3 (HLA-A24-restricted) and study 2 evaluated DLTs of peptides 1-6 (HLA-A24 or A02-restricted). Results: Overall, 18 and 14 patients were enrolled in studies 1 and 2, respectively. No DLTs were observed up to 7.1 mg of the vaccine cocktail. No complete response/partial response was observed. Stable disease was reported in nine and five patients with a disease control rate of 52.9% and 35.7% in studies 1 and 2, respectively. Conclusion: Both vaccines showed good tolerability and potential usefulness against HCC. Clinical trial registration: JapicCTI-121933; JapicCTI-142477",

keywords = "GPC3, HCC, hepatocellular carcinoma, NEIL3, Phase I studies, WDRPUH",

author = "Masafumi Ikeda and Takuji Okusaka and Izumi Ohno and Shuichi Mitsunaga and Shunsuke Kondo and Hideki Ueno and Chigusa Morizane and Kazuto Gemmoto and Hideaki Suna and Yasunori Ushida and Junji Furuse",

note = "Publisher Copyright: {\textcopyright} 2021 Masafumi Ikeda.",

year = "2021",

month = apr,

doi = "10.2217/imt-2020-0278",

language = "English",

volume = "13",

pages = "371--385",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Future Medicine Ltd.",

number = "5",

}

TY - JOUR

T1 - Phase i studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma

AU - Ikeda, Masafumi

AU - Okusaka, Takuji

AU - Ohno, Izumi

AU - Mitsunaga, Shuichi

AU - Kondo, Shunsuke

AU - Ueno, Hideki

AU - Morizane, Chigusa

AU - Gemmoto, Kazuto

AU - Suna, Hideaki

AU - Ushida, Yasunori

AU - Furuse, Junji

PY - 2021/4

Y1 - 2021/4

N2 - Aim: Two peptide cocktail vaccines using glypican-3, WD-repeat-containing protein up-regulated in hepatocellular carcinoma (HCC) and nei endonuclease VIII-like three epitopes were evaluated in advanced HCC in two Phase I studies. Patients & methods: Study 1 evaluated dose-limiting toxicities (DLTs) of peptides 1-3 (HLA-A24-restricted) and study 2 evaluated DLTs of peptides 1-6 (HLA-A24 or A02-restricted). Results: Overall, 18 and 14 patients were enrolled in studies 1 and 2, respectively. No DLTs were observed up to 7.1 mg of the vaccine cocktail. No complete response/partial response was observed. Stable disease was reported in nine and five patients with a disease control rate of 52.9% and 35.7% in studies 1 and 2, respectively. Conclusion: Both vaccines showed good tolerability and potential usefulness against HCC. Clinical trial registration: JapicCTI-121933; JapicCTI-142477

AB - Aim: Two peptide cocktail vaccines using glypican-3, WD-repeat-containing protein up-regulated in hepatocellular carcinoma (HCC) and nei endonuclease VIII-like three epitopes were evaluated in advanced HCC in two Phase I studies. Patients & methods: Study 1 evaluated dose-limiting toxicities (DLTs) of peptides 1-3 (HLA-A24-restricted) and study 2 evaluated DLTs of peptides 1-6 (HLA-A24 or A02-restricted). Results: Overall, 18 and 14 patients were enrolled in studies 1 and 2, respectively. No DLTs were observed up to 7.1 mg of the vaccine cocktail. No complete response/partial response was observed. Stable disease was reported in nine and five patients with a disease control rate of 52.9% and 35.7% in studies 1 and 2, respectively. Conclusion: Both vaccines showed good tolerability and potential usefulness against HCC. Clinical trial registration: JapicCTI-121933; JapicCTI-142477

KW - GPC3

KW - HCC

KW - hepatocellular carcinoma

KW - NEIL3

KW - Phase I studies

KW - WDRPUH

UR - http://www.scopus.com/inward/record.url?scp=85101001949&partnerID=8YFLogxK

U2 - 10.2217/imt-2020-0278

DO - 10.2217/imt-2020-0278

M3 - Article

C2 - 33525928

AN - SCOPUS:85101001949

SN - 1750-743X

VL - 13

SP - 371

EP - 385

JO - Immunotherapy

JF - Immunotherapy

IS - 5

ER -

Phase i studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma

Abstract

Keywords

Access to Document

Fingerprint

Cite this